Last reviewed · How we verify

NCT05418725: BEAT PERS-AF

Ground-Breaking Electroporation-based Intervention for PERSistent Atrial Fibrillation Treatment (BEAT PERS-AF)

Completed NA Last updated 17 June 2025
What this trial tests

NA trial testing PVI and Linear lesion using PEF in Atrial Fibrillation in 83 participants. Completed in 28 May 2025.

Timeline
4 November 2022
Primary endpoint
28 May 2025
28 May 2025

Quick facts

Lead sponsorUniversity Hospital, Bordeaux
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment83
Start date4 November 2022
Primary completion28 May 2025
Estimated completion28 May 2025
Sites9 locations across France, Belgium, Austria, Germany, Czechia

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BEAT AF is a randomized controlled trial aiming to assess the efficacy and the safety of pulsed field energy in persistent AF ablation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05418725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing